Last reviewed · How we verify
TILT-123
At a glance
| Generic name | TILT-123 |
|---|---|
| Also known as | Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123), TNFalpha and IL-2 coding oncolytic adenovirus TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2 |
| Sponsor | TILT Biotherapeutics Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (PHASE1)
- TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma (PHASE1)
- Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer (PHASE1)
- Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (PHASE1, PHASE2)
- Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (PHASE1)
- TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TILT-123 CI brief — competitive landscape report
- TILT-123 updates RSS · CI watch RSS
- TILT Biotherapeutics Ltd. portfolio CI